Cargando…

Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy

Background: Helicobacter pylori eradication containing the potassium-competitive acid blocker, vonoprazan, achieves a higher eradication rate than therapy with proton pump inhibitors (PPIs). Because vonoprazan is mainly metabolized by CYP3A4/5, CYP genotype may affect the eradication rate. We invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Mitsushige, Hira, Daiki, Murata, Masaki, Kawai, Takashi, Terada, Tomohiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599771/ https://www.ncbi.nlm.nih.gov/pubmed/32993151 http://dx.doi.org/10.3390/antibiotics9100645

Ejemplares similares

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population
por: Sugimoto, Mitsushige, et al.
Publicado: (2021)

Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis
por: Sugimoto, Mitsushige, et al.
Publicado: (2020)

Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019)

Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
por: Ishida, Yoshiko, et al.
Publicado: (2006)

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
por: Sue, Soichiro, et al.
Publicado: (2017)

Vonoprazan-Associated Gastric Mucosal Redness in Non-Helicobacter pylori-Infected and Helicobacter pylori-Eradicated Stomach
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
por: Okimoto, Tadayoshi, et al.
Publicado: (2016)

Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis
por: Murata, Masaki, et al.
Publicado: (2020)

Cap polyposis refractory to Helicobacter pylori eradication treated with endoscopic submucosal dissection
por: Murata, Masaki, et al.
Publicado: (2017)

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Sue, Soichiro, et al.
Publicado: (2018)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
por: Tanabe, Hiroki, et al.
Publicado: (2018)

Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
por: Miftahussurur, Muhammad, et al.
Publicado: (2020)

Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis
por: Morino, Yuko, et al.
Publicado: (2021)

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study
por: Lin, Yimin, et al.
Publicado: (2022)

Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
por: Zhang, Wen-Lin, et al.
Publicado: (2023)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
por: Feng, Jia-Hui, et al.
Publicado: (2023)

CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
por: Lin, Tsung-Jung, et al.
Publicado: (2018)

Quinolone-Containing Therapies in the Eradication of Helicobacter pylori
por: Chuah, Seng-Kee, et al.
Publicado: (2014)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
por: Saito, Yoshimasa, et al.
Publicado: (2019)

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication
por: Hu, Yi, et al.
Publicado: (2022)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
por: Sue, Soichiro, et al.
Publicado: (2017)

CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection
por: Auttajaroon, Jeerayuth, et al.
Publicado: (2019)

Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study
por: Sue, Soichiro, et al.
Publicado: (2022)

Efficacy of a Third-Generation High-Vision Ultrathin Endoscope for Evaluating Gastric Atrophy and Intestinal Metaplasia in Helicobacter pylori-Eradicated Patients
por: Uematsu, Junichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7a5b2r4q7p1rte08j9ub7hr7gs